# A Tasisulam and Midazolam Drug Interaction Study in Cancer Patients

> **NCT01209832** · PHASE1 · TERMINATED · sponsor: **Eli Lilly and Company** · enrollment: 11 (actual)

## Conditions studied

- Advanced Cancer

## Interventions

- **DRUG:** Tasisulam
- **DRUG:** Midazolam

## Key facts

- **NCT ID:** NCT01209832
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-09
- **Primary completion:** 2011-01
- **Final completion:** 2011-01
- **Target enrollment:** 11 (ACTUAL)
- **Why stopped:** Terminated based on safety results from another trial
- **Last updated:** 2019-03-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01209832

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01209832, "A Tasisulam and Midazolam Drug Interaction Study in Cancer Patients". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT01209832. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*